NOT FOR DISTRIBUTION
Header cover image

Market Cap

AU$27.0m

Last Updated

2021/05/13 08:43 UTC

Data Sources

Company Financials

Executive Summary

Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Amplia Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ATX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ATX's weekly volatility has decreased from 19% to 10% over the past year.


Market Performance


7 Day Return

-7.8%

ATX

-1.5%

AU Biotechs

-0.7%

AU Market


1 Year Return

183.1%

ATX

-10.9%

AU Biotechs

35.4%

AU Market

Return vs Industry: ATX exceeded the Australian Biotechs industry which returned -10.9% over the past year.

Return vs Market: ATX exceeded the Australian Market which returned 35.4% over the past year.


Shareholder returns

ATXIndustryMarket
7 Day-7.8%-1.5%-0.7%
30 Day-4.1%2.3%0.8%
90 Day-13.0%-1.6%2.5%
1 Year183.1%183.1%-10.0%-10.9%39.6%35.4%
3 Year-43.4%-43.4%59.5%54.3%30.2%14.8%
5 Year-91.9%-92.0%148.2%133.8%61.7%31.7%

Long-Term Price Volatility Vs. Market

How volatile is Amplia Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Amplia Therapeutics undervalued compared to its fair value and its price relative to the market?

2.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ATX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ATX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ATX is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: ATX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATX is good value based on its PB Ratio (2.1x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Amplia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Amplia Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Amplia Therapeutics performed over the past 5 years?

25.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATX is currently unprofitable.

Growing Profit Margin: ATX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ATX is unprofitable, but has reduced losses over the past 5 years at a rate of 25.8% per year.

Accelerating Growth: Unable to compare ATX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.6%).


Return on Equity

High ROE: ATX has a negative Return on Equity (-15.38%), as it is currently unprofitable.


Financial Health

How is Amplia Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ATX's short term assets (A$4.7M) exceed its short term liabilities (A$615.6K).

Long Term Liabilities: ATX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: ATX is debt free.

Reducing Debt: ATX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ATX has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 18.7% each year.


Dividend

What is Amplia Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

John Lambert (55 yo)

1.92yrs

Tenure

AU$239,491

Compensation

Dr. John Lambert, (B.Sc. (Hons), PhD GAICD, has been the Chief Executive Officer at Amplia Therapeutics Limited since June 24, 2019 and its Managing Director and Director since February 6, 2020. Dr. Lamber...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD185.38K) is below average for companies of similar size in the Australian market ($USD289.57K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ATX's management team is seasoned and experienced (5.3 years average tenure).


Board Members

Experienced Board: ATX's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ATX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 62.5%.


Top Shareholders

Company Information

Amplia Therapeutics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Amplia Therapeutics Limited
  • Ticker: ATX
  • Exchange: ASX
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$26.993m
  • Shares outstanding: 107.97m
  • Website: https://www.ampliatx.com

Location

  • Amplia Therapeutics Limited
  • 90 Collins Street
  • Level 21
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings


Biography

Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company’s clinical development pip...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/13 08:43
End of Day Share Price2021/05/13 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.